Blood Cell Technologies LLC is usefully understood as an early-stage start-up: an R&D company focused on identifying and validating novel cellular and diagnostic technologies relevant to human blood disorders. Principals of the firm describe themselves as structured around identifying, validating, and commercializing novel drug targets and compounds that may (could) be being used to diagnose or treat blood cell disorders, enabling clinicians to enhance platelet production in humans by the first-in-class redox-inhibiting compounds
